Bharat Biotech submits Covaxin phase-III clinical trial data to DCGI

The Hyderabad based covid 19 vaccine , Covaxin manufacturing company submitted its phase iii clinical trial data to DCGI, according to Govt. sources.

Bharat Biotech’s Covaxin is one of the three vaccines being used in India . The efficacy of Covaxin was under radar as it had not submiited the stage 3 clinical trial data. The data is expected to get published within a week. It was scheduled to be published in June earlier. 

pic credit: bharatbiotech.com

Why Phase 3 trial data is important ?

Under the phase 3 clinical  trial, investigators keep track of participants for at least six months after the last vaccine dose is administered . The data of those falling sick among the vaccinated and unvaccinated participants helps calculate the efficacy of the vaccine.

The trial also helps to  highlight the possible adverse affects of a vaccine. Favourable phase 3 results of the vaccine’s  efficacy and side-effects leads to the vaccines being approved for general human use.

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

MoralStory.in will use the information you provide on this form to be in touch with you and to provide updates and marketing.